K
KeyMed Biosciences Inc
HKEX:2162
KeyMed Biosciences Inc
HKEX:2162
Price:
53.8
HKD
6.64%
Market Cap:
HK$16.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
CN |
Income Statement
Earnings Waterfall
KeyMed Biosciences Inc
KeyMed Biosciences Inc
Income Statement
KeyMed Biosciences Inc
KeyMed Biosciences Inc
Currency: CNY
| Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Interest Expense |
11
|
6
|
8
|
16
|
17
|
17
|
18
|
17
|
|
| Revenue |
110
N/A
|
210
+91%
|
100
-52%
|
327
+227%
|
354
+8%
|
82
-77%
|
428
+424%
|
872
+104%
|
|
| Gross Profit | |||||||||
| Cost of Revenue |
(17)
|
(20)
|
(3)
|
(15)
|
(37)
|
(26)
|
(12)
|
(42)
|
|
| Gross Profit |
93
N/A
|
191
+105%
|
97
-49%
|
312
+220%
|
317
+2%
|
56
-82%
|
416
+642%
|
830
+100%
|
|
| Operating Income | |||||||||
| Operating Expenses |
(3 910)
|
(558)
|
(576)
|
(700)
|
(751)
|
(846)
|
(1 007)
|
(1 159)
|
|
| Selling, General & Administrative |
(92)
|
(117)
|
(134)
|
(165)
|
(177)
|
(208)
|
(299)
|
(412)
|
|
| Research & Development |
(358)
|
(331)
|
(507)
|
(593)
|
(596)
|
(678)
|
(735)
|
(764)
|
|
| Other Operating Expenses |
(3 459)
|
(110)
|
65
|
58
|
22
|
39
|
27
|
16
|
|
| Operating Income |
(3 817)
N/A
|
(367)
+90%
|
(479)
-30%
|
(388)
+19%
|
(434)
-12%
|
(790)
-82%
|
(591)
+25%
|
(329)
+44%
|
|
| Pre-Tax Income | |||||||||
| Interest Income Expense |
(60)
|
96
|
175
|
130
|
77
|
55
|
83
|
75
|
|
| Non-Reccuring Items |
(16)
|
11
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(3 893)
N/A
|
(260)
+93%
|
(304)
-17%
|
(258)
+15%
|
(356)
-38%
|
(735)
-106%
|
(509)
+31%
|
(254)
+50%
|
|
| Net Income | |||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
(2)
|
(8)
|
(6)
|
(3)
|
|
| Income from Continuing Operations |
(3 893)
|
(260)
|
(304)
|
(258)
|
(358)
|
(743)
|
(515)
|
(257)
|
|
| Income to Minority Interest |
5
|
6
|
(5)
|
(9)
|
(2)
|
(1)
|
(0)
|
(0)
|
|
| Net Income (Common) |
(3 887)
N/A
|
(253)
+93%
|
(308)
-22%
|
(267)
+13%
|
(359)
-35%
|
(743)
-107%
|
(515)
+31%
|
(257)
+50%
|
|
| EPS (Diluted) |
-24.17
N/A
|
-0.94
+96%
|
-1.18
-26%
|
-1
+15%
|
-1.37
-37%
|
-2.84
-107%
|
-1.97
+31%
|
-0.98
+50%
|
|
Switch to:
Switch to:
See Also
Discover More
